Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Cancer Res. 2008 Oct 1;68(19):7718–7722. doi: 10.1158/0008-5472.CAN-08-2042

Figure 3. RhoGAP activities of DLC-1 mutants.

Figure 3

HEK293T cells transfected with indicated GFP fusion constructs were treated with lysophosphatidic acid and then RhoA-GTP levels were analyzed by GST-RBD pull down assay followed by anti-RhoA blotting (top). The expression levels of endogenous RhoA (middle) and recombinant GFP-fusion proteins (bottom) were confirmed by immunoblotting with anti-RhoA and anti-GFP antibodies.